Serum microRNA profiles as prognostic biomarkers for HBV-positive hepatocellular carcinoma

Hao-Tu Zhu; Abdulbaqi M. E. Hasan; Rong-Bin Liu; Zi-Chen Zhang; Xiao Zhang; Jing Wang; Hai-Yun Wang; Fang Wang; Jian-Yong Shao

doi:10.18632/oncotarget.10082

Oncotarget

Oncotarget (a primarily oncology-focused, peer-reviewed, open access journal) aims to maximize research impact through insightful peer-review; eliminate borders between specialties by linking different fields of oncology, cancer research and biomedical sciences; and foster application of basic and clinical science.

Its scope is unique. The term "oncotarget" encompasses all molecules, pathways, cellular functions, cell types, and even tissues that can be viewed as targets relevant to cancer as well as other diseases. The term was introduced in the inaugural Editorial, Introducing Oncotarget.

As of January 1, 2022, Oncotarget has shifted to a continuous publishing model. Papers will now be published continuously within yearly volumes in their final and complete form and then quickly released to Pubmed.

Subscribe to receive alerts once a paper has been published by Oncotarget.

Impact Journals, LLC is the publisher of Oncotarget: www.impactjournals.com.

Impact Journals is a member of the Wellcome Trust List of Compliant Publishers.

Impact Journals is a member of the Society for Scholarly Publishing.

On December 23, 2022, Oncotarget server experienced a DDoS attack. As a result, Oncotarget site was inaccessible for a few hours. Oncotarget team swiftly dealt with the situation and took it under control. This malicious action will be reported to the FBI.

Research Papers:

Serum microRNA profiles as prognostic biomarkers for HBV-positive hepatocellular carcinoma

Hao-Tu Zhu, Abdulbaqi M. E. Hasan, Rong-Bin Liu, Zi-Chen Zhang, Xiao Zhang, Jing Wang, Hai-Yun Wang, Fang Wang and Jian-Yong Shao _

PDF | HTML | Supplementary Files | How to cite

Oncotarget. 2016; 7:45637-45648. https://doi.org/10.18632/oncotarget.10082

Metrics: PDF 2256 views | HTML 2250 views | ?

Abstract

Hao-Tu Zhu1,*, Abdulbaqi M. E. Hasan1,*, Rong-Bin Liu1, Zi-Chen Zhang1, Xiao Zhang1, Jing Wang1, Hai-Yun Wang1, Fang Wang1, Jian-Yong Shao1

1State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, and Department of Molecular Diagnostics, Sun Yat-sen University Cancer Center, Guangzhou, 510060, China

*These authors contributed equally to this work

Correspondence to:

Jian-Yong Shao, email: [email protected]

Keywords: serum microRNA, biomarkers, hepatocellular carcinoma, prognosis, deep sequencing

Received: January 28, 2016 Accepted: May 28, 2016 Published: June 15, 2016

ABSTRACT

To establish serum microRNA profiles as prognostic biomarkers in hepatocellular carcinoma patients (HCCs), we used deep sequencing to screen serum microRNAs in a discovery set .Twelve up-regulated serum miRNAs were selected for qPCR analysis in a training set. MiR-192-5p and miR-29a-3p were identified and associated with HCC prognosis. HCCs with high concentrations of miR-192-5p and miR-29a-3p had poorer overall survival (OS) and progression-free survival (PFS) than those with low concentrations. We calculated a prognostic index (PI) score and classified patients into low-, medium- and high-risk groups. OS and PFS among the 3 groups from the training set were significantly different (all P < 0.05). PI (PI_OS, PI_PFS) score was the only independent prognostic predictor for OS and PFS of HCCs in the training set. These results were further confirmed in a validation set. In conclusion, differentially expressed serum miRNAs can be helpful for predicting survival in HCCs.

All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 10082

Publication Alerts

Research Papers:

Serum microRNA profiles as prognostic biomarkers for HBV-positive hepatocellular carcinoma

Abstract